Inhibikase Therapeutics, Inc.
IKT
$2.36
$0.114.89%
| Weiss Ratings | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.80 | |||
| Price History | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 20.41% | |||
| 30-Day Total Return | 9.26% | |||
| 60-Day Total Return | -40.55% | |||
| 90-Day Total Return | -9.58% | |||
| Year to Date Total Return | -28.27% | |||
| 1-Year Total Return | 17.41% | |||
| 2-Year Total Return | -34.44% | |||
| 3-Year Total Return | -72.69% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -43.81% | |||
| 52-Week Low % Change | 110.71% | |||
| Price | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.20 | |||
| 52-Week Low Price | $1.12 | |||
| 52-Week Low Price (Date) | Sep 25, 2024 | |||
| 52-Week High Price (Date) | Dec 18, 2024 | |||
| Valuation | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 163.70M | |||
| Enterprise Value | 160.67M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.72 | |||
| Earnings Per Share Growth | -25.92% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -33.19 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.36 | |||
| Enterprise Value/EBITDA (TTM) | -8.02 | |||
| Enterprise Value/EBIT | -8.01 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 8.88M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 678 392 3419 | |||
| Address | 3350 Riverwood Parkway SE Atlanta, GA 30339 | |||
| Website | www.inhibikase.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -112.68% | |||
| Return on Equity | -- | |||
| Income Statement | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 0.00 | |||
| Total Revenue (TTM) | 0.00 | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -13.02M | |||
| EBITDA (TTM) | -20.04M | |||
| EBIT (TTM) | -20.06M | |||
| Net Income (TTM) | -19.57M | |||
| Net Income Avl. to Common (TTM) | -19.57M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -25.74% | |||
| EPS Diluted (TTM) | -2.72 | |||
| EPS Diluted Growth (Q YOY) | 12.77% | |||
| Balance Sheet | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.24M | |||
| Cash Per Share (Q) | $0.37 | |||
| Total Current Assets (Q) | 4.19M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -530.60K | |||
| Current Ratio (Q) | 0.854 | |||
| Book Value Per Share (Q) | -$0.07 | |||
| Total Assets (Q) | 4.38M | |||
| Total Current Liabilities (Q) | 4.91M | |||
| Total Debt (Q) | 216.90K | |||
| Total Liabilities (Q) | 4.91M | |||
| Total Common Equity (Q) | -530.60K | |||
| Cash Flow | IKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -358.10K | |||
| Cash from Financing (TTM) | 3.66M | |||
| Net Change in Cash (TTM) | -13.95M | |||
| Levered Free Cash Flow (TTM) | -10.29M | |||
| Cash from Operations (TTM) | -17.24M | |||
